Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients
Open Access
- 15 September 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 84 (2) , 233-241
Abstract
Background: Since COVID-19 outbreak, hydroxychloroquine (HCQ) has been tested for effective therapies, and the relevant researches have shown controversial results. Methods: Systematic review and meta-analysis were conducted after a thorough search of relevant studies from databases. Trials that have evaluated HCQ for COVID-19 treatment were recruited for statistical analysis with fixed- and random-effect models. Results: Nine trials involving 4112 patients were included in present meta-analysis. It was seen that HCQ-azithromycin (HCQ-AZI) combination regimen increased the mortality rate in COVID-19 (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.63–3.36) patients; however, it also showed benefits associated with the viral clearance in patients (OR, 27.18; 95% CI, 1.29–574.32). HCQ-alone when used as a therapy in COVID-19 did not reveal significant changes in mortality rate, clinical progression, viral clearance, and cardiac QT prolongation. Subsequent subgroup analysis showed that HCQ treatment could decrease mortality rate and progression to severe illness in severely infected COVID-19 patients (OR, 0.27; 95% CI, 0.13–0.58). A lower risk of mortality rate was also noted in the stratified group of >14 days follow-up period (OR, 0.27; 95% CI, 0.13–0.58) compared to ≤14 days follow-up period group that conversely showed an increased mortality rate (OR, 2.09; 95% CI, 1.41–3.10). Conclusion: Our results indicated that HCQ-AZI combination treatment increased mortality rate in patients with COVID-19, but it also showed benefits associated with viral clearance in patients. HCQ-alone used for treatment has revealed benefits in decreasing the mortality rate among severely infected COVID-19 group and showed potential to be used for COVID-19 treatment in long-term follow-up period group. Accordingly, more rigorous, large-scale, and long follow-up period studies in patients with COVID-19 are needed.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Chloroquine and hydroxychloroquine as available weapons to fight COVID-19International Journal of Antimicrobial Agents, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- The outbreak of COVID-19: An overviewJournal of the Chinese Medical Association, 2020
- QT prolongation predicts short-term mortality independent of comorbidityEP Europace, 2019
- Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired PneumoniaClinical Infectious Diseases, 2017
- Cardiovascular Risks with Azithromycin and Other Antibacterial DrugsNew England Journal of Medicine, 2013
- Long-term prognosis in community-acquired pneumoniaCurrent Opinion in Infectious Diseases, 2013
- Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitroActa Tropica, 2006
- Drug induced QT prolongation and torsades de pointesHeart, 2003
- The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.Journal of Epidemiology and Community Health, 1998